Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
Findings show berberine (BBR) as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.
Combination of simvastatin with berberine improves the lipid-lowering efficacy.
Antioxidant and Anti-Inflammatory Activities of Berberine in the Treatment of Diabetes Mellitus
- Zheng Li, Yanyan Geng, Jian-Dong Jiang, Wei-Jia Kong
- Biology, ChemistryEvidence-based complementary and alternative…
- 11 February 2014
Mechanisms of the antioxidant and anti-inflammatory activities of BBR were complex, which involved multiple cellular kinases and signaling pathways, such as AMP-activated protein kinase (AMPK), mitogen-activatedprotein kinases (MAPKs), nuclear factor erythroid-2-related factor-2 (Nrf2) pathway, and nuclear factor-κB (NF-κBs) pathway.
Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes
Four major BBR metabolites (M1-M4) were identified after phase-I transformation in rat liver, and cell-free reactions showed that CYP2D6, CYP1A2 and CYP3A4 seemed to be the dominant CYP450 isoenzymes transforming BBR into its metabolites M2 and M3.
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Human low-density lipoprotein receptor gene and its regulation
Upregulation of liver LDL receptor expression is effective in treating hypercholesterolemia and this review focuses on the latest progress on the mechanisms and regulation of the LDL receptor gene expression.
Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway
- Li-Li Qu, Bin Yu, Zheng Li, Wenxiao Jiang, Jian-Dong Jiang, Wei-Jia Kong
- Biology, ChemistryPhytotherapy research : PTR
- 1 March 2016
It is demonstrated that GSTD activates the AMPK/Nrf2 pathway, ameliorates oxidative stress/proinflammatory response and improves lipid metabolism in NAFLD.
Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
- Ying-hong Li, Peng Yang, Jian-Dong Jiang
- Chemistry, BiologyJournal of medicinal chemistry
- 22 January 2009
Twenty-nine derivatives of berberine or pseudoberberine were designed, semisynthesized, and evaluated for their up-regulatory activity on the low-density-lipoprotein receptor (LDLR) expression to consider compound 2 a promising cholesterol-lowering drug candidate.
Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms
Data from the present review support that agents targeting chronic inflammation may have a broad application prospect for the prevention and treatment of cancer in the future.